Please assess the completion status of the following clinical trial:

Trial Title: Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with T. trichiura by Kato Katz.~* Body weight \>15kg.~* Accepts participation~Exclusion Criteria:~* Albendazole and/or mebendazol treatment in the previous 3 months.~* Allergy to the study drugs~* Acute medical conditions~* Clinical trial participation in the previous 3 months.~* Pregnancy.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole 400mg (Type: ACTIVE_COMPARATOR): Albendazole 400mg in single dose
- Albendazole/Ivermectin (Type: EXPERIMENTAL): Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
- Albendazole 400mg x 3 (Type: EXPERIMENTAL): Albendazole 400mg/day for 3 consecutive days
- Albendazole/Ivermectin x 3 (Type: EXPERIMENTAL): Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).